Health Catalyst, Inc. (NASDAQ:HCAT) Shares Bought by Principal Financial Group Inc.

Principal Financial Group Inc. raised its stake in Health Catalyst, Inc. (NASDAQ:HCAT) by 6.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,469 shares of the company’s stock after buying an additional 1,907 shares during the quarter. Principal Financial Group Inc.’s holdings in Health Catalyst were worth $188,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its position in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock valued at $41,000 after buying an additional 5,232 shares during the last quarter. Perfromance Wealth Partners LLC purchased a new stake in Health Catalyst during the second quarter worth about $64,000. EntryPoint Capital LLC purchased a new stake in Health Catalyst during the first quarter worth about $98,000. Virtus Investment Advisers Inc. purchased a new stake in Health Catalyst during the first quarter worth about $115,000. Finally, SG Americas Securities LLC purchased a new stake in Health Catalyst during the second quarter worth about $187,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on HCAT shares. Piper Sandler cut their price target on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 26th. JPMorgan Chase & Co. boosted their price target on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price target on shares of Health Catalyst in a research note on Tuesday, May 21st. Cantor Fitzgerald reiterated an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a research note on Tuesday, August 20th. Finally, Stephens cut their price target on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, Health Catalyst presently has a consensus rating of “Moderate Buy” and an average price target of $11.42.

Insider Activity at Health Catalyst

In related news, COO Daniel Lesueur sold 5,208 shares of the company’s stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at $954,572.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Kevin Lee Freeman sold 7,500 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Daniel Lesueur sold 5,208 shares of the stock in a transaction that occurred on Wednesday, July 3rd. The shares were sold at an average price of $6.15, for a total value of $32,029.20. Following the completion of the sale, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at $954,572.25. The disclosure for this sale can be found here. Insiders sold 34,037 shares of company stock valued at $236,872 over the last three months. 2.70% of the stock is owned by corporate insiders.

Health Catalyst Stock Up 5.2 %

Shares of HCAT opened at $8.44 on Monday. The stock has a 50 day moving average price of $7.05 and a 200 day moving average price of $6.89. The company has a market capitalization of $498.26 million, a price-to-earnings ratio of -4.56 and a beta of 1.31. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.04. The firm had revenue of $75.90 million during the quarter, compared to the consensus estimate of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.21) earnings per share. On average, equities analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current fiscal year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.